Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7991081 | 0.88 | PDE4A (0.55) | PDE4AKCNH2 | |
| SCHEMBL7976960 | 0.85 | PDE4A (0.74) | PDE4AKCNH2 | |
| SCHEMBL7977050 | 0.85 | PDE4A (0.66) | PDE4AKCNH2 | |
| SCHEMBL7991153 | 0.84 | PDE4A (0.72) | PDE4AKCNH2 | |
| SCHEMBL7376251 | 0.81 | PDE4A (0.67) | PDE4AKCNH2 | |
| SCHEMBL7383406 | 0.81 | PDE4A (0.65) | PDE4AKCNH2 | |
| SCHEMBL7376254 | 0.80 | PDE4A (0.66) | PDE4AKCNH2 | |
| SCHEMBL7905267 | 0.80 | PDE4A (1.00) | PDE4AKCNH2 | |
| SCHEMBL7380926 | 0.80 | PDE4A (0.76) | PDE4AKCNH2 | |
| SCHEMBL7899052 | 0.80 | PDE4A (1.00) | PDE4AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6180650-B1 | ANTIINFLAMMATORY AGENTS; RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTITUMOR AGENTS | MERCK FROSST CANADA & CO. (CA) | 2001-01-30 | — | — | US | claimed |
| EP-1180100-A2 | HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS PDE 4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2002-02-20 | — | — | EP | disclosed |
| US-6180650-B1 | ANTIINFLAMMATORY AGENTS; RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTITUMOR AGENTS | MERCK FROSST CANADA & CO. (CA) | 2001-01-30 | — | — | US | disclosed |
| WO-2000064874-A2 | HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS PDE 4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2000-11-02 | — | — | WO | disclosed |